Analyst spotlights a compelling path forward for DMD program and looks to key catalysts in fourth quarter.
RNN’s Phase 2a results have analyst optimistic on RX-3117 drug for patients running out of options.
Analyst Joseph Pantginis of H.C.
On Tuesday, Capricor Therapeutics, Inc. (NASDAQ:CAPR) was granted FDA Rare Pediatric Disease Designation for CAP-1002, the company’s treatment for Duchenne muscular dystrophy (DMD) and …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) offered a key glimpse into its advanced muscle invasive bladder cancer (MIBC) Phase 2a trial at the American Society …
Drug maker Sophiris Bio Inc (NASDAQ:SPHS) released its earnings report for the first quarter of 2017 and is one step closer to beginning Phase …
H.C.
In a research report issued Thursday, H.C.
Following Sophiris Bio Inc’s (NASDAQ:SPHS) fourth-quarter and 2016 financial results released yesterday coupled with last week’s update on its prostate cancer program, Rodman …
Sophiris Bio Inc (NASDAQ:SPHS) shares are rising almost 17% on back of Rodman & Renshaw analyst Joseph Pantginis initiating coverage on SPHS with …
